2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, Non-Biological Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1639 Bleximenib population pharmacokinetics and exposure-response analyses from the phase 1/2 camelot-1 study

Lu Zhang, Prathap Nagaraja Shastri, PhD2, Jia Ji3, Jafar Sadik Shaik4, Yaming Su5, Lucille Ferrante, MD6, Anita J. Kumar7, Trevor Tucker8, Nahor Haddish-Berhane, PhD9, Kathryn Packman, PhD10
1 Johnson & Johnson, Spring House, Pennsylvania, United States
2 Johnson & Johnson, Spring House, Pennsylvania, United States
3 Johnson & Johnson, Spring House, Pennsylvania, United States
4 Johnson & Johnson, Spring House, Pennsylvania, United States
5 Johnson & Johnson, Raritan, New Jersey, United States
6 Johnson & Johnson, Spring House, Pennsylvania, United States
7 Johnson & Johnson, Spring House, Pennsylvania, United States
8 Johnson & Johnson, Spring House, Pennsylvania, United States
9 Johnson & Johnson, Spring House, Pennsylvania, United States
10 Johnson & Johnson, Cambridge, Massachusetts, United States

Background: Although treatment for acute leukemia (AL) has advanced, patients with relapsed/refractory (R/R) disease continue to have poor outcomes. Bleximenib (JNJ-75276617) is a highly potent oral menin-KMT2A inhibitor. It has demonstrated clinical activity and a manageable safety profile in hard-to-treat patients with R/R acute myeloid leukemia (AML) harboring KMT2A rearrangements (KMT2Ar) or NPM1 mutations (NPM1m) at the recommended phase 2 dose (RP2D; 100 mg twice daily [BID] preceded by a 50 mg BID step-up dose for 14 days). Here we report interim phase 1/2 population pharmacokinetics (popPK) and exposure-response (E-R) analyses supporting the recommended dose regimen. 

Methods: This popPK analysis included 4254 plasma samples from 310 participants (pts) with R/R AL across all dose levels. Nonlinear mixed-effects modeling (NONMEM v7.5.0) was used. Covariates included demographics (age, sex, race, ethnicity, body weight), laboratory values, Eastern Cooperative Oncology Group performance status, gene alteration, formulation, and concomitant use of strong, moderate, or mild CYP3A4 inhibitors. Bleximenib exposure metrics, accumulation ratio, and effective half-life were derived from individual Bayesian post hoc PK parameters at the RP2D. E-R efficacy analyses were conducted separately for pts with R/R KMT2Ar or NPM1m AML receiving bleximenib at the RP2D. E-R safety analyses pooled phase 1 and 2 data across both genetic alterations. 

Results: Bleximenib PK was well characterized by a 2-compartment linear model with first-order absorption and elimination. For a typical pt weighing 70 kg, the population estimates for apparent clearance (CL/F), central volume of distribution (Vc/F), and peripheral volume of distribution (Vp/F) were 18.6 liters (L)/hour, 322 L, and 858 L, respectively. Bleximenib exposure increase was approximately dose proportional from 15 to 100 mg BID. The mean effective half-life was 26.5 hours. 

Based on popPK modeling, concomitant use of strong CYP3A4 inhibitors with bleximenib increased bleximenib area under the curve (AUC0-12hr,ss) by approximately 2-fold (geometric mean ratio: 2.09; 90% confidence interval, 1.79-2.43). Bleximenib exposure was also comparable across pts with mild to moderate renal or mild hepatic impairment (compared with pts with normal function), and across age, race, sex, gene alteration, and formulation subgroups, with no dose adjustments required. 

In pts treated at the RP2D included in the E-R efficacy analyses (total, N = 123; KMT2Ar, n = 54; NPM1m, n = 69), for each gene alteration no clinically meaningful E-R relationships were observed for complete remission/complete remission with partial hematological recovery, best overall response rate, overall survival, or event-free survival across exposure quartiles, indicating that exposures at the RP2D lie on the flat portion of the E-R curve. In the E-R safety analysis (total, N = 281; phase 1, n = 141; phase 2, n = 140), no clinically meaningful E-R relationships were identified between bleximenib exposure and the incidence of cytopenias (any grade or grade ≥ 3 adverse events [AEs]; including thrombocytopenia, neutropenia, febrile neutropenia, and anemia) or differentiation syndrome (any grade or grade ≥ 3 AEs). 

Conclusions: Bleximenib demonstrated a favorable oral PK profile in adult pts with R/R AML, with a mean effective half-life of 26.5 hours. The flat E-R relationship observed for efficacy at the RP2D suggests that exposures are within the range associated with maximal or near-maximal efficacy. Flat E-R relationships for safety (including QTc [Abdul-Hay, et al. EHA 2026. Abstract EHA-1824]) across a wide range of bleximenib exposures, together with a consistent safety profile for bleximenib with or without concomitant strong CYP3A4 inhibitors, supports a broad exposure-safety window. These findings support flexible clinical use of bleximenib at the RP2D across a broad exposure range, including in the context of concomitant strong CYP3A4 inhibitor use and in pts with mild to moderate renal or mild hepatic impairment with no dose adjustments required based on these intrinsic factors. These results further support 100 mg BID (with a 50 mg BID step-up for 14 days) as the bleximenib recommended dose for adults with R/R AML harboring KMT2Ar or NPM1m.

Prathap Nagaraja Shastri, PhD: Johnson & Johnson - Stock (publicly traded); Johnson & Johnson - Current Employment